To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). Official Title. An Open-label, Multi-center LBA12 Efficacy and safety of IBI351 (GFH925), a selective
FDA approves phase III trial of GenFleet's KRAS G12C inhibitor Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic Being developed by GenFleet Therapeutics, GFH925 is a novel, orally active, potent KRAS G12C inhibitor designed to effectively target the GTP/
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for NMPA has granted Breakthrough Therapy Designation (BTD) for IBI351 (GFH925) for the treatment of advanced non-small cell lung cancer patients with KRASG12C
GFH925 (KRAS G12C Inhibitor) Granted with Breakthrough Therapy The US Food and Drug Administration (FDA) has granted approval for GenFleet Therapeutics' Phase III clinical trial of GFH925, a KRAS G12C inhibitor. LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC):
Study Details | NCT05005234 | A Study of GFH925 in Patients With Innovent and GenFleet Announce Exclusive Global License KROCUS: A phase II study investigating the efficacy and safety of
GFH925 is a novel, orally active, potent KRAS G12C inhibitor designed to effectively target the GTP/GDP exchange, an essential step in Background: Fulzerasib (GFH925), a KRAS G12C inhibitor, showed substantial efficacy in previously treated NSCLC patients (pts) as monotherapy. Fulzerasib has recently received accelerated approval in China for adult NSCLC patients with the KRAS G12C mutation after prior systemic therapy
RAS mutations are the most prevalent genetic alterations in human tumors, accounting for 30% of all cases. Among these mutations, KRAS G12C emerged as the Background: IBI351 (GFH925) is an irreversibly covalent inhibitor of KRASG12C and has demonstrated promising anti-tumor activity with
Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C 說到IPO新股上市,近期值得關注的是代號02595的勁方醫藥—B #港股#IPO 【分享開啟🔔小鈴鐺】【Subscribe and share opening🔔】 說到#IPO #新股上市,近期值得關注的是代號02595的勁方醫藥—B。這家專注於創新藥物研發的生物製藥公司將於2025年9月19日